Marker Therapeutics (MRKR) Cash & Current Investments (2010 - 2026)

Marker Therapeutics (MRKR) has reported Cash & Current Investments for 17 consecutive years, with $15.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 14.04% year-over-year to $15.6 million; the TTM figure through Mar 2026 stood at $15.6 million (up 14.04% YoY), while the FY2025 annual figure was $17.0 million, down 11.2% from the prior year.
• Cash & Current Investments fell to $15.6 million in Q1 2026 per MRKR's latest filing, from $17.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $28.8 million in Q1 2022 and bottomed at $6.4 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $15.7 million across 5 years, with a median of $15.6 million in 2026.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 77.79% — and 2025, when it soared 111.01%.
• Marker Therapeutics' Cash & Current Investments stood at $11.8 million in 2022, then grew by 28.26% to $15.1 million in 2023, then advanced by 27.01% to $19.2 million in 2024, then retreated by 11.2% to $17.0 million in 2025, then dropped by 8.37% to $15.6 million in 2026.
• Business Quant data shows MRKR's Cash & Current Investments at $15.6 million in Q1 2026, $17.0 million in Q4 2025, and $19.0 million in Q3 2025.